Weekly Rundown: Key Catalysts for Small-Cap Stocks (November 24–28)

From recent disclosures to corporate shifts, we’ve highlighted the top small-cap catalysts to watch. This week’s preview (November 24–28) also includes a few notable Q4 catalysts that could influence market sentiment as we head into the final stretch of the year.

--

Companies with Material Events for This Week (November 24–28):

• AMWL will participate in a panel titled "Transforming a Sick-Care System into a Health-Care System," taking place virtually at 8:00 a.m. ET during the BTIG Digital Health Forum on November 24.

• NAMM will host a webcast and conference call for a business update at 8:00 a.m. ET on Monday, November 24.

• DCGO will take part in the BTIG Digital Health Forum on November 24. CEO Lee Bienstock will join a panel titled "Care Gap Closure and Mobile Health Support" at 11:00 a.m. ET and participate in one-on-one meetings.

• LFMD will also participate in the BTIG Digital Health Forum on November 24, joining a virtual panel titled "Creating a Scalable Virtual Primary Care and Obesity Health Platform" at 4:00 p.m. ET and will be available for 1x1 virtual meetings.

• VZLA will host a webcast at 10:00 a.m. PT (1:00 p.m. ET) on November 24 to discuss the Panuco Project Feasibility Study.

• SLI will be participating in the virtual Bank of America Critical Materials Conference on Monday, November 24.

• CRNT will be participating in Needham Tech Week on November 24 in a virtual format.

• VNDA is expecting an expedited FDA re-review of the partial clinical hold on long-term studies of tradipitant for motion sickness by November 26.

• FFAI continues advancing its EAI ecosystem and expects the first FX Super One pre-production vehicle to come off the U.S. line by year-end, with the first delivery in the UAE on November 27.

• NWL declared a quarterly cash dividend of $0.07 per share, payable on December 15, 2025, to shareholders of record as of November 28.

• WKSP will open orders for its SOLIS Solar Cover and COR Portable Energy System on November 28.

• GRI announced the FDA has cleared its IND application and it has received authorization from the UK and Australia to begin a Phase 2a biomarker study for GRI-0621 in IPF. Enrollment completed in July 2025, and topline results from the study are expected by the end of November. Interim data suggest anti-fibrotic biomarker changes and no safety concerns were observed.

• IMRN expects topline results from the Travelan® Uniformed Services University P2TD gut health study by the end of November, following earlier delays from the government shutdown.

• VCIG has approved a special dividend consisting of 10% of the share capital of its cybersecurity and AI subsidiary, V Gallant Limited, to be distributed to shareholders. The official record date will be announced within 7 to 14 days, placing the announcement window between November 24 and December 1.

• DVLT confirmed that Nasdaq will not assign an ex-dividend date for its previously announced distribution of Dream Bowl 2026 Meme Coins. Only shareholders of record as of November 25, 2025, will be eligible for the token distribution. This applies to holders of both DVLT and SCLX stock.

Early December Catalysts:

• RVSN signed a non-binding term sheet to acquire 51% of Quantum Transportation Ltd., a quantum computing and AI firm. The deal aims to integrate quantum-AI into Rail Vision’s safety systems. The transaction is expected to close in early to mid-December 2025, pending definitive agreements and regulatory approvals.

• SIDU is advancing development of Lonestar’s secure data payload integrated into the LizzieSat-5 platform. With mission milestones progressing, the next phase is a Preliminary Design Review (PDR) scheduled for early December 2025. The mission supports sovereign orbital data storage with edge processing and X-band communications.

As we near the last month in the 4th quarter, we looked through some near-term catalysts yet to come:

• RVPH has a pre-NDA meeting with the FDA planned for Q4 2025 to discuss the approval pathway for brilaroxazine in schizophrenia.

• NCNA expects to release initial data from the expansion study of NUC-7738 in Q4 2025.

• BCDA reported that the FDA has accepted its annual report, and the company plans to request a meeting in Q4 2025 to discuss the approvability of the FDA-designated Breakthrough CardiAMP System.

• GUTS is expecting to report 6-month data from the REVEAL-1 Cohort in Q4 2025.

• SLXN is on track with clinical trial preparations for SIL204, with toxicology studies progressing and regulatory submissions to Israel’s Ministry of Health anticipated in Q4 2025.

• OGEN anticipates multiple Q4 2025/Q1 2026 milestones, including final HREC amendment approval, initiation of its Phase IIa clinical trial in Australia, and IND submission prep for U.S.-based Phase IIb trials.

• MGX is advancing its MGX-001 hemophilia A program and expects to hold a pre-IND meeting with the FDA in Q4 2025.

• KLTR signed a definitive agreement to acquire eSelf.ai, with closing expected in Q4 2025. It also signed an exclusive partnership with Telestream to migrate customers from the Sherpa Stream platform, which is being sunset by year-end.

• AGEN has initiated a global registrational Phase 3 trial (BATTMAN/CCTG CO.33) in MSS/pMMR colorectal cancer, launching in Q4 2025 across 100+ global sites.

• ALXO remains on track to dose the first patient in its Phase 2 ASPEN-09 Breast Cancer trial in Q4 2025, which will evaluate evorpacept efficacy based on CD47 expression levels.

• BMEA is progressing its icovamenib development with a food effect study expected to complete in December 2025. Two new Phase II trials (COVALENT-211 and COVALENT-212) are also expected to initiate in Q4 2025.

• DCGO plans to launch Longitudinal Care Services with a California-based insurer in Q4 2025, targeting 10,000 under-engaged plan members with chronic and preventive care.

• ACIU anticipates multiple Q4 2025 milestones across its pipeline, including interim Phase 2 data for ACI-7104.056 and ACI-24.060, lead declarations for Morphomer-based programs, IND/CTA filings for ACI-19764, and Phase 1 readouts for two PET tracer programs.

• INMB will present additional CORDStrom™ data in Q4 2025, along with Phase 2 MINDFuL imaging data in Alzheimer’s and final results from the INKmune CARE-PC trial.

• OVID expects first-in-human data for OV350, its IV KCC2 direct activator, to be released in Q4 2025.

• BIYA signed a stock purchase agreement to acquire 100% of Starfish Technology-FZE, with the transaction expected to close in Q4 2025, subject to customary conditions.

• CLIR received an order for comprehensive testing of a hydrogen-capable burner from a major petrochemical customer, with final performance data expected to be delivered in Q4 2025.

• BURU is targeting November 30, 2025, for the finalization of an Italian “Network Contract” to formalize shared operations and integrated R&D execution.

• GTBP plans to submit an IND for GTB-5550 TriKE® targeting B7H3-expressing solid tumors by late December 2025 or January 2026.

--

Disclaimer: All content provided by BigTimePennys Report is for informational purposes only. The information provided should not be considered as a substitute for professional advice, analysis, or guidance. Any investment decisions made based on the information provided are solely at the user's own risk. BigTimePennys Report are not liable for any losses or damages incurred as a result of using this information. BigTimePenny is not operated by a licensed broker, a dealer, or a registered investment adviser. The Securities Litigation Reform Act of 1995 provides safe harbor protection for forward-looking statements made by companies or individuals. It should be noted that any forward-looking statements made by BigTimePennys Report, its authors, are not guarantees of future performance or results. These statements are subject to risks, uncertainties, and assumptions that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. The content provided by BigTimePennys Report does not constitute an endorsement, recommendation, or solicitation to buy, sell, or hold any securities or investment products. BigTimePennys Report, its authors, do not endorse or recommend any specific investment strategies, securities, or companies. It is crucial to conduct thorough research and seek advice from a qualified professional before making any investment decisions. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. The user assumes full responsibility for the use of the information provided by BigTimePennys Report. BigTimePennys Report, its authors, disclaim any liability for any direct, indirect, or consequential damages arising from the use or reliance on the information provided. Users should exercise their own judgment and discretion when interpreting and utilizing the information provided. Please note that the content provided by BigTimePennys Report is based on available information and sources believed to be reliable. However, market conditions and regulations may change over time, and there may be inaccuracies or errors in the information provided. It is recommended to verify the information with current and reliable sources before making any investment decisions. Investing in micro-cap companies is highly speculative and carries an extremely high degree of risk. BigTimePenny is not a fiduciary by virtue of any person's use of or access to this content. We were NOT compensated for this article.